Compare Abeona Therapeutics Inc (ABEO) vs S&P500 ETF (SPY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs S&P500 ETF — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while S&P500 ETF trades at $743.26. Which is the better fit depends on your goals.
| ABEO | SPY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $759.55 |
52-Week Low | $4.17 | $620.34 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SPY trades at $747.62, up 0.38% with technical indicators showing mixed signals - moving averages are bullish while oscillators suggest caution. The ETF is approaching key resistance at $750-$758 levels. Recent market sentiment reflects debate between AI-driven growth optimism and concerns about market leverage and valuations.
The outlook remains cautiously optimistic with S&P 500 targets ranging from 8,000-8,800 by year-end, though strategists warn of potential 10-20% corrections. Key risks include excessive market leverage, high valuations, and sector rotation away from tech. Earnings growth and reasonable valuations may support further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
